Author(s):
Dinna Devi, Nuzulia Irawati, Yanwirasti, Imam Budi Putra, Yudha Endra Pratama
Email(s):
nuzuliairawati@med.unand.ac.id
DOI:
10.52711/0974-360X.2025.00282 
Address:
Dinna Devi1,2, Nuzulia Irawati3*, Yanwirasti3, Imam Budi Putra4, Yudha Endra Pratama5
1Doctoral Program, Department of Biomedical, Faculty of Medicine, Andalas University, 25166, Padang, Indonesia.
2Faculty of Medical, Abdurrab University, 28292, Pekanbaru, Riau, Indonesia.
3Department of Biomedical, Faculty of Medicine, Andalas University, 25166, Padang, Indonesia.
4Department of Dermatology and Venerology, Faculty of Medicine, Universitas Sumatera Utara, 20155, Medan, Indonesia.
5Department of Biotechnology, Faculty of Animal Science, Andalas University, 25166, Padang Indonesia.
*Corresponding Author
Published In:
Volume - 18,
Issue - 5,
Year - 2025
ABSTRACT:
Atopic dermatitis and psoriasis are inflammatory skin conditions that affect close to 3% of the global population. Rats are research animals that are very useful as research media. Imiquimod (IMQ) is an immune activator often used ion or molecule known as a ligand for Toll-Like Receptors 7 (TLR7), including Toll-Like Receptors (TLRS). In addition, imiquimod has a psoriasis-like inflammatory effect. This study aims to develop psoriasis mice implementing the inducing chemical with Imiquimod (IMQ). This study assesses Psoriasis Area Severity Index (PASI) and histopathology scores after administering IMQ to the study rats. The PASI score is observed every three days until the ninth day. The hair on the Wistar rats’ back was continuously removed and given 62,5 mg IMQ 5% cream for nine days. Furthermore, the area severity index of psoriasis uses induration (thickness), the level of erythema (redness) and desquamation (scaling) on every skin rat. Then, histopathology was observed in each rat. The erythema signs, thickening, and scales appear on the back's skin on the third until sixth days following IMQ administration. The maximum score was seen on day 9, with all three indicators and the cumulative score indicating increased physical characteristics. Microscopically, it showed thickening of the stratum corneum (hyperkeratosis), epidermal hyperplasia (acanthosis), increased skin vascularity, and inflammatory infiltration of mast cells, macrophages, and inflammatory lymphocytes. This research succeeded in developing Wistar rats as a model for causes of skin inflammation, such as psoriasis induced by IMQ 5% as an inducing agent to psoriasis.
Cite this article:
Dinna Devi, Nuzulia Irawati, Yanwirasti, Imam Budi Putra, Yudha Endra Pratama. Histopathological Observation and Psoriasis area Severity Index Scoring of Imiquimod-induced Psoriasis in Experimental Animals. Research Journal of Pharmacy and Technology. 2025;18(5):1975-2. doi: 10.52711/0974-360X.2025.00282
Cite(Electronic):
Dinna Devi, Nuzulia Irawati, Yanwirasti, Imam Budi Putra, Yudha Endra Pratama. Histopathological Observation and Psoriasis area Severity Index Scoring of Imiquimod-induced Psoriasis in Experimental Animals. Research Journal of Pharmacy and Technology. 2025;18(5):1975-2. doi: 10.52711/0974-360X.2025.00282 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-5-5
REFERENCES:
1. Tejasavi Mahajan, Navdeep Singh, Kamya Goyal, Shammy Jindal, Vinay Pandit, M.S. Ashawat. Recent Updates on Psoriasis: A Review. Asian Journal of Pharmaceutical Research. 2022; 12(1): 76-3. doi: 10.52711/2231-5691.2022.00012
2. Imafuku S, Honma M, Okubo Y, Komine M, Ohtsuki M, Morita A, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese Study. J Dermatol. 2016; 43: 1011–7. doi/10.1111/1346-8138.13306
3. Komal V. Kakade, Rahul D. Khaire. A Review on Psoriasis. International Journal of Technology. 2022; 12(2): 47-2. doi: 10.52711/2231-3915.2022.00009
4. Shivi Sondhi, Navdeep Singh, Shammy Jindal. Natural Remedies used in the Treatment of Psoriasis: A short Review. Asian J. Pharm. Res. 2021; 11(1): 43-45. doi: 10.5958/2231-5691.2021.00009.5
5. Georgescu S-R, Tampa M, Caruntu C, Sarbu M-I, Mitran C-I, Mitran M-I, et al. Advances in Understanding the Immunological Pathways in Psoriasis. Int J Mol Sci. 2019; 20: 739.
6. Rouxel O, Lehuen A. Mucosal-associated invariant T cells in autoimmune and immune-mediated diseases. Immunol Cell Biol. 2018; 96: 618–29. doi/10.1111/imcb.12011
7. Boehncke W-H, Schön MP. Psoriasis. Lancet. 2015; 386: 983–94.
8. Tejasavi Mahajan, Navdeep Singh, Kamya Goyal, Shammy Jindal, Vinay Pandit, M.S. Ashawat. Recent Updates on Psoriasis: A Review. Asian Journal of Pharmaceutical Research. 2022; 12(1): 76-3. doi: 10.52711/2231-5691.2022.00012
9. Schön MP, Manzke V, Erpenbeck L. Animal models of psoriasis—highlights and drawbacks. J Allergy Clin Immunol. 2021; 147: 439–55.
10. Parab S, Doshi G. The Experimental Animal Models in Psoriasis Research: A Comprehensive Review. Int Immunopharmacol. 2023; 117: 109897.
11. Gudjonsson JE, Ding J, Johnston A, Tejasvi T, Guzman AM, Nair RP, et al. Assessment of the Psoriatic Transcriptome in a Large Sample: Additional Regulated Genes and Comparisons with In Vitro Models. J Invest Dermatol . 2010; 130: 1829–40.
12. Dowlatshahi EA, van der Voort EA., Arends LR, Nijsten T. Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2013; 169: 266–82.
13. Murali Badanthadka, Lidwin D’Souza. Imiquimod-Induced Psoriasis Mice Model: A Promising Tool for Psoriasis Research?. Research J. Pharm. and Tech. 2020; 13(7): 3508-3515. doi: 10.5958/0974-360X.2020.00621.6
14. Wolfram D, Morandi EM, Eberhart N, Hautz T, Hackl H, Zelger B, et al. Differentiation between Acute Skin Rejection in Allotransplantation and T-Cell Mediated Skin Inflammation Based on Gene Expression Analysis. Biomed Res Int. 2015; 2015: 1–11.
15. Rabeony H, Pohin M, Vasseur P, Petit-Paris I, Jégou J-F, Favot L, et al. IMQ-induced skin inflammation in mice is dependent on IL-1R1 and MyD88 signaling but independent of the NLRP3 inflammasome. Eur J Immunol. 2015; 45: 2847–57. doi/10.1002/eji.201445215
16. Zhang Y, Yan J, Li Z, Zheng J, Sun Q. Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells Alleviate Psoriasis-like Skin Inflammation. J Interf Cytokine Res. 2022; 42: 8–18. doi/10.1089/jir.2021.0146
17. Jyothi SL, Krishna KL, Ameena Shirin VK, Sankar R, Pramod K, Gangadharappa HV. Drug delivery systems for the treatment of psoriasis: Current status and prospects. J Drug Deliv Sci Technol. 2021; 62: 102364.
18. Parmar K, Jagtap C, Katare N, Dhobi M, Prasad S. Development of a psoriatic-like skin inflammation rat model using imiquimod as an inducing agent. Indian J Pharmacol. 2021; 53: 125.
19. I.E. Otuokere, F.J. Amaku. Conformation Analysis and Self-Consistent Field Energy of Immune Response Modifier, 1-(2-methylpropyl)-1H-imidazo[4,5]quinolin-4-amine (Imiquimod). Asian J. Res. Pharm. Sci. 2015; 5(3): 175-180. doi: 10.5958/2231-5659.2015.00026.0
20. Lin YK, Yang SH, Chen CC, Kao HC, Fang JY. Using Imiquimod-Induced Psoriasis-Like Skin as a Model to Measure the Skin Penetration of Anti-Psoriatic Drugs. Simon M, editor. PLoS One. 2015;10:e0137890.
21. Liu A, Zhao W, Zhang B, Tu Y, Wang Q, Li J. Cimifugin ameliorates imiquimod-induced psoriasis by inhibiting oxidative stress and inflammation via NF-κB/MAPK pathway. Biosci Rep. 2020; 40.
22. Gangadhar Hari, Anusha Prabhu, Chaitanyamayee Kalakota, Jeslin Johnson, Kufaila Mansoor, Rekha R Shenoy, Karkala Sreedhara Ranganath Pai, Krishnadas Nandakumar. Research Journal of Pharmacy and Technology. 2022; 15(10): 4469-2. doi: 10.52711/0974-360X.2022.00749
23. Prakoeswa FRS, Hidayat S, Satria YAA, Awanis GS. Faktor-Faktor yang Dapat Memengaruhi Keseimbangan Th17/Treg: Review Article. HIGEIA (Journal Public Heal Res Dev. 2022;6.
24. Daniel P, Mecklenburg M, Massiah C, Joseph MA, Wilson C, Parmar P, et al. Non-invasive positive pressure ventilation versus endotracheal intubation in treatment of COVID-19 patients requiring ventilatory support. Am J Emerg Med. 2021; 43: 103–8.
25. Costa S, Marini O, Bevilacqua D, DeFranco AL, Hou B, Lonardi S, et al. Role of MyD88 signaling in the imiquimod-induced mouse model of psoriasis: focus on innate myeloid cells. J Leukoc Biol. 2017; 102: 791–803.
26. El Malki K, Karbach SH, Huppert J, Zayoud M, Reißig S, Schüler R, et al. An Alternative Pathway of Imiquimod-Induced Psoriasis-Like Skin Inflammation in the Absence of Interleukin-17 Receptor A Signaling. J Invest Dermatol. 2013; 133: 441–51.
27. Jabeen M, Boisgard A-S, Danoy A, El Kholti N, Salvi J-P, Boulieu R, et al. Advanced Characterization of Imiquimod-Induced Psoriasis-Like Mouse Model. Pharmaceutics. 2020; 12: 789.
28. Navdeep Singh, Shivi Sondhi, Shammy Jindal, Vinay Pandit, Mahendra Singh Ashawat. Treatment and Management for patients with mild to severe Psoriasis: A Review. Asian J. Pharm. Res. 2020; 10(4):286-292. doi: 10.5958/2231-5691.2020.00049.0
29. Wu H, Ou J, Li K, Wang T, Nandakumar KS. Comparative studies on mannan and imiquimod induced experimental plaque psoriasis inflammation in inbred mice. Clin Exp Immunol. 2023; 211: 288–300.
30. OuYang Q, Pan Y, Luo H, Xuan C, Liu J, Liu J. MAD ointment ameliorates Imiquimod-induced psoriasiform dermatitis by inhibiting the IL-23/IL-17 axis in mice. Int Immunopharmacol. 2016;39:369–76.
31. van der Fits L, Mourits S, Voerman JSA, Kant M, Boon L, Laman JD, et al. Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis. J Immunol. 2009; 182: 5836–45.
32. Pietrzak A, Chabros P, Grywalska E, Pietrzak D, Kandzierski G, Wawrzycki B, et al. Serum concentration of interleukin 6 is related to inflammation and dyslipidemia in patients with psoriasis. Adv Dermatology Allergol. 2020; 37: 41–5.
33. Creamer D, Allen MH, Sousa A, Poston R, Barker JNWN. Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis. Br J Dermatol. 1997; 136: 859–65.
34. Jabeen M, Boisgard AS, Danoy A, El Kholti N, Salvi JP, Boulieu R, et al. Advanced Characterization of Imiquimod-Induced Psoriasis-Like Mouse Model. Pharm Charact Imiquimod-Induced Psoriasis-Like Mouse Model. 2020; 12: 789.
35. Vogt A, Wischke C, Neffe AT, Ma N, Alexiev U, Lendlein A. Nanocarriers for drug delivery into and through the skin — Do existing technologies match clinical challenges? J Control Release. 2016; 242: 3–15.
36. Nadeem A, Al-Harbi NO, Al-Harbi MM, El-Sherbeeny AM, Ahmad SF, Siddiqui N, et al. Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC/IL-17A pathway modulation. Pharmacol Res. 2015; 99: 248–57.
37. Lofano G, Mancini F, Salvatore G, Cantisani R, Monaci E, Carrisi C, et al. Oil-in-Water Emulsion MF59 Increases Germinal Center B Cell Differentiation and Persistence in Response to Vaccination. J Immunol. 2015; 195: 1617–27.
38. Su Y, Huang J, Zhao X, Lu H, Wang W, Yang XO, et al. Interleukin-17 receptor D constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammation. Sci Immunol. 2019;4. doi/10.1126/sciimmunol.aau9657
39. Sumithra. M, Mohamed Majeed. A, Chitra. V. Cell Lines and Animal Models of Psoriasis. Research J. Pharm. and Tech. 2020; 13(3):1601-1608. doi: 10.5958/0974-360X.2020.00290.5
40. Mariam Mahmoud Taha, Zainab Thamer Shwait Al-Asady. Evaluation of the Effectiveness of Antioxidants and TNF-α in Iraqi Patients with Psoriasis treated with Etanercept. Research J. Pharm. and Tech. 2019; 12(2): 665-668. doi: 10.5958/0974-360X.2019.00118.5
41. Itoh T, Hatano R, Komiya E, Otsuka H, Narita Y, Aune TM, et al. Biological Effects of IL-26 on T Cell–Mediated Skin Inflammation, Including Psoriasis. J Invest Dermatol. 2019; 139: 878–89.